Avid Bioservices Inc (CDMO)

[pphmtoolong]

The anti-PS platform is only valuable if an effective anti-PS drug is found. Based on testing to date, Bavituimab has not proved it is The Anti-PS drug. Boy do we all wish it was.

Meanwhile, some other company may come up with The Anti-PS drug. If they do, they will have to pay Peregrine IMO based on Peregrine's extensive anti-PS intellectual property.

At least Avid is growing rapidly. Additionally, Bavituximab may have some place in the anti-PS arsenal. The next group of Bavi-immunotherapy trials might establish this.

GLTA, Paul